ELAN vs ZTS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: ZTS is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ELAN and ZTS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ELAN and ZTS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Elanco Animal Health was spun out of Eli Lilly in 2018 and became one of the largest standalone animal health companies in the world after buying Bayer Animal Health in 2020. The business splits roughly into Pet Health (flea and tick parasiticides such as Credelio and Seresto, the dermatology drug Zenrelia, pain products such as Galliprant) and Farm Animal (cattle, poultry, swine and aqua-adjacent products including Rumensin, Experior and the methane-reducing feed additive Bovaer in the US). Revenue comes through veterinary clinics, distributors, retail and e-commerce channels, and from farm producers who buy on economics rather than sentiment, which makes the two halves behave quite differently across a cycle.

Full ELAN guide

Zoetis (ZTS) is the world's largest animal health company, developing and selling medicines, vaccines, diagnostics, and other products for both companion animals (pets like dogs and cats) and livestock (cattle, swine, poultry, and fish). Spun out of Pfizer in 2013, it holds leading positions across dermatology, parasiticides, pain, vaccines, and other categories, with well-known franchises such as Apoquel and Cytopoint for pet itch and allergic skin conditions, the Simparica line of parasiticides, and Librela for osteoarthritis pain in dogs. Companion animal products, driven by the long-run humanization of pets and rising spending on their care, have become the larger and faster-growing part of the business, while livestock provides a more staple, protein-demand-linked base. Zoetis sells through veterinarians in the United States and internationally, invests heavily in research and development to sustain its innovation pipeline, and benefits from patents, brand loyalty, and deep vet relationships. Headquartered in Parsippany, New Jersey, it is widely viewed as a defensive-growth leader on the structural trend of people spending more on animal health, though it faces cyclical pet-visit softness, pricing pressure, and rising competition.

Full ZTS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ELAN drivers: The new pet blockbusters; Margin and leverage repair.
• ZTS drivers: Leader in a structurally growing market; Innovation-driven franchises and pipeline.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Competition is the central risk: Zoetis is larger, better capitalized and defends the parasiticide and dermatology categories aggressively, and Merck, Boehringer Ingelheim and others are active in the same clinics. For ZTS, zoetis faces near-term pressure from softer veterinary visit volumes and increased price sensitivity among pet owners, which have weighed on its companion-animal business and prompted more than one guidance cut in 2026; analysts expect earnings to fall about 3% this year, with Q3 and Q4 EPS each projected about 11-12% lower than a year earlier.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ELAN if you believe its drivers more; ZTS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ELAN and ZTS guides.

ELAN. At roughly $23.50 a share the stock trades near 21x the midpoint of 2026 adjusted EPS guidance and about 18x the 2027 consensus of ~$1.29, and near ~15x enterprise value to EBITDA once net debt is included. That is still a discount to Zoetis on most multiples, which reflects the leverage and the slower legacy portfolio rather than a disagreement about the new launches. The shares are up about 15% over one year but have given back about 8% in three months, so the multiple has compressed slightly even as estimates held.

ZTS. Zoetis has long been valued as a high-quality, defensive-growth compounder at a premium price-to-earnings multiple, but after the 2026 guidance cuts and a roughly 37% year-to-date decline it traded near 12 times forward earnings as of October 16, 2026, closer to a value multiple than its history. The market is pricing in stalled companion-animal growth, softer Librela demand and trade-down by pet owners, against still-high margins and about $2 billion of annual free cash flow. The 15 covering analysts have a mean target near $93.50, and the November 5, 2026 third-quarter report is the next test of whether the outlook has stabilized.

Headline figures (approximate, October 2026): ELAN shows revenue (ttm) ~$5.02B, q2 2026 revenue / adjusted eps ~$1.37B, up ~10% reported / ~$0.34 vs ~$0.27 estimate, fy 2026 revenue guidance ~$5.09B to ~$5.14B, fy 2026 adjusted eps guidance ~$1.10 to ~$1.16 (consensus ~$1.14); ZTS shows revenue (ttm) ~$9.5 billion; Q2 2026 roughly flat YoY, q2 2026 revenue / adjusted eps ~$2.47 billion / ~$1.87 (vs ~$1.85 est.), operating / net margin (ttm) ~41% / ~28%, net income (ttm) ~$2.6 billion.

ELAN and ZTS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ELAN and ZTS exposure against your real portfolio. It is not an investment adviser.